PL3341355T3 - Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego - Google Patents
Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowegoInfo
- Publication number
- PL3341355T3 PL3341355T3 PL16854531T PL16854531T PL3341355T3 PL 3341355 T3 PL3341355 T3 PL 3341355T3 PL 16854531 T PL16854531 T PL 16854531T PL 16854531 T PL16854531 T PL 16854531T PL 3341355 T3 PL3341355 T3 PL 3341355T3
- Authority
- PL
- Poland
- Prior art keywords
- difluoromethylenyl
- cyclopent
- addiction
- epilepsy
- ene
- Prior art date
Links
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 title 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 title 1
- 206010012335 Dependence Diseases 0.000 title 1
- FBLNZOCTNRXJQD-YFKPBYRVSA-N N[C@H]1C=C(CC1=C(F)F)C(O)=O Chemical compound N[C@H]1C=C(CC1=C(F)F)C(O)=O FBLNZOCTNRXJQD-YFKPBYRVSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 230000000937 inactivator Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239330P | 2015-10-09 | 2015-10-09 | |
| EP16854531.7A EP3341355B1 (en) | 2015-10-09 | 2016-10-10 | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
| PCT/US2016/056245 WO2017062942A2 (en) | 2015-10-09 | 2016-10-10 | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3341355T3 true PL3341355T3 (pl) | 2021-03-08 |
Family
ID=58488679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16854531T PL3341355T3 (pl) | 2015-10-09 | 2016-10-10 | Kwas (S)-3-amino-4-(difluorometylenylo)cyklopent-1-eno-1-karboksylowy i związki pokrewne jako dezaktywatory aminotransferazy GABA do leczenia padaczki, uzależnienia oraz raka wątrobowokomórkowego |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9670141B2 (pl) |
| EP (1) | EP3341355B1 (pl) |
| JP (1) | JP6841821B2 (pl) |
| KR (1) | KR20180052782A (pl) |
| CN (1) | CN108137484B (pl) |
| AU (1) | AU2016334396B2 (pl) |
| BR (1) | BR112018007026B1 (pl) |
| CA (1) | CA3001330A1 (pl) |
| CL (1) | CL2018000914A1 (pl) |
| CO (1) | CO2018003828A2 (pl) |
| DK (1) | DK3341355T3 (pl) |
| ES (1) | ES2825349T3 (pl) |
| HK (1) | HK1253002A1 (pl) |
| HU (1) | HUE053429T2 (pl) |
| IL (1) | IL258516A (pl) |
| LT (1) | LT3341355T (pl) |
| MX (1) | MX2018004302A (pl) |
| PE (1) | PE20190349A1 (pl) |
| PL (1) | PL3341355T3 (pl) |
| PT (1) | PT3341355T (pl) |
| WO (1) | WO2017062942A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
| US20200000757A1 (en) * | 2017-02-08 | 2020-01-02 | Ovid Therapeutics Inc. | Methods of treating seizure disorders and prader-willi syndrome |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| JP2021512920A (ja) * | 2018-02-08 | 2021-05-20 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
| KR20210009306A (ko) * | 2018-03-29 | 2021-01-26 | 오비드 테라퓨틱스 인크. | 눈 장애의 치료에서 (1s, 3s)-3-아미노-4-(디플루오로메틸리덴)시클로펜탄-1-카르복실산 및 (s)-3-아미노-4-(디플루오로메틸에닐)시클로펜트-1-엔-1-카르복실산의 용도 |
| US10822301B2 (en) | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| JP7475055B2 (ja) | 2018-05-25 | 2024-04-26 | ノースウェスタン ユニバーシティ | （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法 |
| MX2020013290A (es) | 2018-06-07 | 2021-04-29 | Ovid Therapeutics Inc | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo. |
| US11203596B2 (en) | 2019-02-25 | 2021-12-21 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| WO2020206234A1 (en) | 2019-04-03 | 2020-10-08 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| CN110935495B (zh) * | 2019-11-29 | 2021-02-23 | 中国科学院电子学研究所 | Gaba和电生理微纳同步传感检测芯片及其制备方法 |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| CN117321025A (zh) * | 2021-03-03 | 2023-12-29 | 西北大学 | 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸 |
| WO2024010840A1 (en) * | 2022-07-06 | 2024-01-11 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| IL177609A (en) * | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
| WO2011106692A2 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| TWI468403B (zh) * | 2011-08-30 | 2015-01-11 | Gilead Sciences Inc | 用於治療成癮之ａｌｄｈ－２抑制劑 |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
-
2016
- 2016-10-10 CN CN201680059069.9A patent/CN108137484B/zh active Active
- 2016-10-10 PE PE2018000517A patent/PE20190349A1/es unknown
- 2016-10-10 EP EP16854531.7A patent/EP3341355B1/en active Active
- 2016-10-10 WO PCT/US2016/056245 patent/WO2017062942A2/en active Application Filing
- 2016-10-10 AU AU2016334396A patent/AU2016334396B2/en active Active
- 2016-10-10 MX MX2018004302A patent/MX2018004302A/es unknown
- 2016-10-10 ES ES16854531T patent/ES2825349T3/es active Active
- 2016-10-10 US US15/289,480 patent/US9670141B2/en active Active
- 2016-10-10 CA CA3001330A patent/CA3001330A1/en active Pending
- 2016-10-10 HU HUE16854531A patent/HUE053429T2/hu unknown
- 2016-10-10 BR BR112018007026-2A patent/BR112018007026B1/pt active IP Right Grant
- 2016-10-10 KR KR1020187013228A patent/KR20180052782A/ko not_active Application Discontinuation
- 2016-10-10 DK DK16854531.7T patent/DK3341355T3/da active
- 2016-10-10 LT LTEP16854531.7T patent/LT3341355T/lt unknown
- 2016-10-10 PL PL16854531T patent/PL3341355T3/pl unknown
- 2016-10-10 PT PT168545317T patent/PT3341355T/pt unknown
- 2016-10-10 JP JP2018517734A patent/JP6841821B2/ja active Active
-
2017
- 2017-05-04 US US15/586,730 patent/US9993449B2/en active Active
-
2018
- 2018-04-05 IL IL258516A patent/IL258516A/en active IP Right Grant
- 2018-04-09 CL CL2018000914A patent/CL2018000914A1/es unknown
- 2018-04-10 CO CONC2018/0003828A patent/CO2018003828A2/es unknown
- 2018-05-29 US US15/991,323 patent/US20180271816A1/en not_active Abandoned
- 2018-09-26 HK HK18112366.1A patent/HK1253002A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3341355T3 (da) | 2020-10-26 |
| WO2017062942A3 (en) | 2018-03-01 |
| JP6841821B2 (ja) | 2021-03-10 |
| EP3341355B1 (en) | 2020-09-30 |
| CN108137484A (zh) | 2018-06-08 |
| MX2018004302A (es) | 2018-11-09 |
| AU2016334396B2 (en) | 2021-04-08 |
| EP3341355A2 (en) | 2018-07-04 |
| PT3341355T (pt) | 2020-10-21 |
| US20170239202A1 (en) | 2017-08-24 |
| BR112018007026B1 (pt) | 2022-06-21 |
| JP2018531941A (ja) | 2018-11-01 |
| US20170101364A1 (en) | 2017-04-13 |
| WO2017062942A2 (en) | 2017-04-13 |
| PE20190349A1 (es) | 2019-03-07 |
| KR20180052782A (ko) | 2018-05-18 |
| LT3341355T (lt) | 2020-11-10 |
| US9670141B2 (en) | 2017-06-06 |
| CL2018000914A1 (es) | 2018-08-31 |
| CA3001330A1 (en) | 2017-04-13 |
| ES2825349T3 (es) | 2021-05-17 |
| HUE053429T2 (hu) | 2021-07-28 |
| EP3341355A4 (en) | 2019-04-10 |
| CO2018003828A2 (es) | 2018-07-19 |
| HK1253002A1 (zh) | 2019-06-06 |
| US9993449B2 (en) | 2018-06-12 |
| US20180271816A1 (en) | 2018-09-27 |
| CN108137484B (zh) | 2021-02-12 |
| AU2016334396A1 (en) | 2018-04-19 |
| BR112018007026A2 (pt) | 2018-10-16 |
| IL258516A (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253002A1 (zh) | 作為用於治療癲癇、成癮和肝細胞癌的gaba氨基轉移酶滅活劑的(s)-3-氨基-4-(二氟亞甲基)環戊-1-烯-1-羧酸及有關化合物 | |
| ZA201708039B (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| FI3906789T3 (fi) | Initioivia huputettuja oligonukleotidialukkeita 5’-huputettujen RNA:iden syntetisoimiseksi | |
| IL248538B (en) | Vector viruses unrelated to the treatment of lysosomal storage disorders | |
| LT3109223T (lt) | Junginys, skirtas karbamido turinčių trąšų apdorojimui | |
| HK1252996A1 (zh) | 用於治療癲癇的方法 | |
| PT3519569T (pt) | Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses | |
| IL252042B (en) | Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma | |
| EP3107538A4 (en) | Combination therapy for hepatocellular carcinoma | |
| IL264950A (en) | Combined treatments for the treatment of malignant liver cell carcinoma | |
| EP3362205A4 (en) | METHODS FOR IMPROVING THERMAL TREATMENT OF CAST PARTS | |
| HK1258449A1 (zh) | 伊非曲班治療系統性硬化 | |
| ZA201803046B (en) | Process for recovering metals | |
| EP3624800A4 (en) | TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| HK1250624A1 (zh) | 用於治療心血管障礙的方法 | |
| PT3310711T (pt) | Processo para a produção de cianeto de sódio | |
| GB201603752D0 (en) | Treatment of hypothyroidism | |
| GB201521542D0 (en) | Methods for the treatment of cardiovascular disorders | |
| GB201506228D0 (en) | Methods For The Treatment Of Cardivascular Disorders | |
| GB201513991D0 (en) | Methods for the treatment of cardiovascular disorders | |
| GB201513344D0 (en) | Methods for the treatment of Cardiovascular disorders | |
| GB201507109D0 (en) | Methods for the treatment of cardiovascular disorders | |
| ZA201408372B (en) | Therapeutic biologic for treatment of hepatocellular carcinoma |